NCT05917106 Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
| NCT ID | NCT05917106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinling Hospital, China |
| Condition | Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2022-12-26 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2022-12-26 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Eligibility Criteria
Inclusion Criteria: * Newly diagnosed renal cell carcinoma * Without any treatment * Agree and accept radical surgical treatment * Signed written informed consent * ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1 * Follow up protocol and related procedures Exclusion Criteria: * Had other cancers * Had received any antitumor therapy before * Known or suspected active autoimmune disease * Informed consent is not possible due to medical or psychiatric problems * Have clinical symptoms or diseases of the heart that are not well controlled * Patients judged by the investigators to be unsuitable for inclusion in this study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05917106 clinical trial?
This trial is open to participants of all sexes, studying Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05917106 currently recruiting?
Yes, NCT05917106 is actively recruiting participants. Contact the research team at septsoul@hotmail.com for enrollment information.
Where is the NCT05917106 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05917106 clinical trial?
NCT05917106 is sponsored by Jinling Hospital, China. The trial plans to enroll 450 participants.